India’s Achievement Under Mission COVID Suraksha
The Covid 19 pandemic was challenges to global scientific community for preventing and managing the infection. The government of India has praised globally by the international community for its vision to manage pandemic. The Mission COVID Suraksha was announced by Government of India at the total cost of Rs 300 Crore, under the Atmanirbhar Bharat 3.0 Package.
Four COVID Vaccines under Mission COVID Suraksha
India has developed 4 COVID vaccine under the Mission Covid Suraksha for Emergency Use Authorization ( EUA ).
ZyCoV-D
- World’s first and India’s indigenously developed DNA Vaccine.
- It received EUA on 20th August for 12 year and above age group.
CORBEVAXTM
- India’s first protein subunit vaccine.
- It received EUA on 29th December 2021 for 18 year and above, age group, 12-18 years age group and 5-12 years age group.
- It also included as precaution dose on 4th June 2022.
GEMCOVACTM-19
- World’s 1st and India’s indigenously developed mRNA Vaccine.
- It received EUA on 28th June, 2022.
iNCOVACC
- World’s 1st and India’s indigenously developed COVID 19 Vaccine.
- It received EUA on 6th September, 2022 for primary 18 years and above.
- It also included as homologous and heterologous booster dose.
Read More: Mission COVID Suraksha
You may also like to read these articles also: